Hadi Falahatpisheh

发表

Anatomic and Clinical Pathology Characterization of Drug-Induced Sinusoidal Obstruction Syndrome (Veno-Occlusive Disease) in Cynomolgus Macaques

R. Kohnken, Hadi Falahatpisheh, K. Janardhan, 2021, Toxicologic pathology.

Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring

J. Kreeger, H. Gerber, T. Coskran, 2016, Clinical Cancer Research.

Activation profiles of HSPA5 during the glomerular mesangial cell stress response to chemical injury

K. Ramos, A. Nañez, E. Tiffany-Castiglioni, 2007, Cell stress & chaperones.

PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers

F. Loganzo, C. J. O’Donnell, J. Lucas, 2020, Molecular Cancer Therapeutics.

Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape.

E. Tarcsa, J. C. Kalvass, Hadi Falahatpisheh, 2020, Drug discovery today. Technologies.

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions

Samuel A. Williams, O. Foord, M. Aujay, 2017, Science Translational Medicine.

Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade

Z. Kan, F. Loganzo, J. Lucas, 2022, Molecular cancer therapeutics.

Improving the Safety Profile of ADCs

Hadi Falahatpisheh, M. Guffroy, Martin B. Finkelstein, 2018 .

Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions

Kathryn Loving, O. Foord, M. Aujay, 2015, Clinical Cancer Research.